<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6883">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017313</url>
  </required_header>
  <id_info>
    <org_study_id>A-ES-52014-224</org_study_id>
    <nct_id>NCT03017313</nct_id>
  </id_info>
  <brief_title>To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients</brief_title>
  <acronym>ANAREN</acronym>
  <official_title>A Prospective Post Marketing Non Interventional Study to Evaluate the Criteria on Which Renewal of LHRH Analogue Treatment is Made in Patients With Prostate Cancer Locally Advanced or Metastatic.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol, is to determine the percentage of patients for whom the initial
      LHRH prescription has been renewed
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients for whom the initial LHRH prescription (the prescription at the baseline visit) has been renewed at first follow-up visit (same type, same formulation).</measure>
    <time_frame>First follow-up visit (occurs 3 to 6 months from baseline)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients for whom the initial LHRH prescription has been renewed at each visit.</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients having switched from a 3 months to a 6 months and also 6 months to 3 months formulation at each visit.</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients starting a 6-month formulation at baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>The decision to prescribe a LHRH analogue as a 3- or 6-months formulation will be made prior to and independently from the decision to enrol the subject. This decision should be made in accordance with the usual medical practice of the concerned investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons leading to a switch of formulation (patient) presented as proportion of patients</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons leading to a switch of formulation (physician) presented as proportion of physicians</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Criteria for choice of formulation at start of hormonal treatment taking into consideration the patient characteristics and his disease status.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the Quality of Life Questionnaire QLQ-PR25 score compared to baseline and each visit.</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between physician and patient satisfaction and the evolution of the biological parameters (Prostate-specific antigen)</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients for which the initial prescription (the prescription at the baseline visit) of a LHRH analogue (3 or 6 months) has been stopped and later on renewed (intermittent treatment)</measure>
    <time_frame>Baseline, between 3 to 6 months, 12 months, 18 months and 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH analogues</intervention_name>
    <description>3-or 6-month formulations</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Prostate cancer locally advanced or metastasic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men diagnosed of locally advanced or metastatic prostate cancer scheduled to
             receive androgen deprivation therapy with a 3 or 6 month LHRH analogue including
             those requiring neo-adjuvant or adjuvant androgen deprivation therapy in association
             with radiotherapy

          -  Patients having provided written informed consent

          -  Patients mentally fit for completing a self-administrated questionnaire

        Exclusion Criteria:

          -  Patients participating in another clinical study at the time of inclusion

          -  Patients with another severe malignant disease

          -  Life expectancy of less than 12 months

          -  Patients already treated with a LHRH analogue within the last year
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Hernandez Yuste, BSc, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>December 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
